Cardinal Health reports fiscal year-end results today against a backdrop of unusually uniform analyst conviction — and a stock that has moved meaningfully since the last preview was filed.
The analyst setup remains the dominant story. Since early July, UBS, Citigroup, B of A Securities, and TD Cowen have all raised price targets, maintaining Buy or Outperform ratings throughout. UBS now carries the highest target at $274; the consensus mean is $262.53, roughly 9% above the current price of $240.26. That gap has narrowed since the prior article noted 7% upside from $236.40 — the stock has ticked higher, but the Street has kept pace by lifting targets. JP Morgan remains the only visible holdout, sitting at Neutral. Its $215 target looks increasingly disconnected from where the stock actually trades, and should be treated with caution given how far consensus has moved above it since that note was filed in May.
The bull and bear debate turns on a few concrete questions. Bulls point to Cardinal's expanding footprint in radiopharmaceuticals and specialty distribution, free cash flow durability, and a capital return program that has supported the stock through a volatile macro backdrop. EPS momentum ranks in the 92nd percentile on a 30-day basis and the 87th percentile over 90 days — both unusually strong readings that suggest estimate revisions have been running in Cardinal's favour. Bears are more focused on the structural picture: generic-drug tailwinds from the last patent-cliff cycle are fading, the US pharmaceutical wholesale market is intensifying competitively, and the GMPD segment carries meaningful international exposure at a time when tariff and geopolitical risk remains elevated. The options market is not adding much conviction either way — the put/call ratio of 0.73 is fractionally below its 20-day average of 0.74, essentially neutral into the print.
Short interest tells a largely quiet story. Bears who have been leaning on the name have retreated meaningfully: SI as a percentage of the free float dropped from roughly 3.9% in early July to 2.9% now — a 25% decline over 30 days. Borrowing costs are negligible at 0.35%, and share availability is effectively uncapped, with no evidence of any squeeze dynamic in the lending market. Peers MCK and COR both gained more than 8% on the week, suggesting sector tailwinds are real rather than idiosyncratic to Cardinal. The one prior earnings data point available showed a modest 2.2% one-day gain followed by a 4.8% five-day decline after the May print — a reminder that the stock can give back ground even after a headline beat.
Today's print is therefore less a test of whether Cardinal can grow and more a test of whether the specialty and pharmaceutical distribution business can deliver a margin profile that justifies targets that have been moving steadily upward all summer.
See the live data behind this article on ORTEX.
Open CAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
